The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas(397 views) Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
Affiliations: Dept. Molec. Clin. Endocrinol. O., Federico II University of Naples, Via S. Pansini 5, 80131 Napoli, Italy
References: Lamberts, S.W.J., Van Der Lely, A.-J., De Herder, W.W., Hofland, L.J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J.C., Landolt, A.M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Ikuyama, S., Nawata, H., Kato, K., Karshima, T., Ibayashi, H., Nagakaki, H., Specific somatostatin receptors on human pituitary adenoma cell membrane (1985) J. Clin. Endocrinol. Metab., 61, p. 666
Reubi, J.C., Heitz, P.U., Landolt, A.M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J.C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F.F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Lamberts, S.W.J., Uitterlinden, P., Schuijff, P.C., Klijn, G.C., Therapy of acromegaly with sandostatin: The predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical "cure" (1988) Clin. Endocrinol., 29, p. 411
Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Lombardi, G., Prediction of efficacy of octreotide therapy in patients with acromegaly (1996) J. Clin. Endocrinol. Metab., 81, p. 2356
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1990) Endocr. Rev., 12, p. 450
Faglia, G., Bazzoni, N., Spada, A., Arosio, M., Ambrosi, B., Spinelli, F., Sara, R., Lunghi, F., In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of radioiodinated analog of somatostatin ([123-I]SDZ 204-090) (1991) J. Clin. Endocrinol. Metab., 73, p. 850
Ur, E., Mather, S.J., Bomanji, J., Ellison, D., Britton, K.E., Grossman, A.B., Wass, J.A.H., Besser, G.M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Broson-Chazot, F., Houzard, C., Ajzenberg, C., Noucaudie, M., Duet, M., Mundler, O., Marchandise, X., Warnet, A., Somatostatin receptor imaging in somatroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide (1997) Clin. Endocrinol., 47, p. 589
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.-J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Plöckinger, U., Bäder, M., Hopfenmüller, H., Saeger, W., Quabbe, H.-J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E.A., Verhoeff, N.P.L.G., Meylaerts, S.A.G., Miedema, A.R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Colao, A., Di Sarno, A., Landi, M.L., Cirillo, S., Samacchiaro, F., Facciolli, G., Pivonello, R., Lombardi, G., Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage (1997) J. Clin. Endocrinol. Metab., 82, p. 3574
Bakker, W.H., Albert, R., Bruns, C., Breeman, W.A.P., Hofland, L.J., Marbach, P., Pless, J., Krenning, E.P., [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T.W.A., Kwekkeboom, D.J., V'ant Verlaat, J.W., Reubi, J.-C., Krenning, E.P., Lamberts, S.W.J., Croughs, R.J.M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J.-C., Landolt, A.M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
Merola, B., Colao, A., Ferone, D., Selleri, A., Di Sarno, A., Marzullo, P., Biondi, B., Lombardi, G., Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm. Res., 40, p. 149
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue an chiasmal dysfunction from pituitary macroadenomas (1989) J. Neurosurg., 71, p. 687
Chanson, P., Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? (1997) Eur. J. Endocrinol., 136, p. 359
Lamberts, S. W. J., Van Der Lely, A. -J., De Herder, W. W., Hofland, L. J., Octreotide (1996) N. Engl. J. Med., 334, p. 24
Reubi, J. C., Landolt, A. M., High density of somatostatin receptors in pituitary tumors from acromegalic patients (1984) J. Clin. Endocrinol. Metab., 59, p. 1148
Reubi, J. C., Heitz, P. U., Landolt, A. M., Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses (1987) J. Clin. Endocrinol. Metab., 65, p. 65
Reubi, J. C., Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors (1989) Int. Congr. Ser., 864, p. 285. , Casanueva F. F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology Amsterdam, Excepta Medica
Ur, E., Mather, S. J., Bomanji, J., Ellison, D., Britton, K. E., Grossman, A. B., Wass, J. A. H., Besser, G. M., Pituitary imaging using a labelled somatostatin analogue in acromegaly (1992) Clin. Endocrinol., 36, p. 147
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. -J., Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J. Clin. Endocrinol. Metab., 79, p. 1416
Pl ckinger, U., B der, M., Hopfenm ller, H., Saeger, W., Quabbe, H. -J., Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology (1997) Eur. J. Endocrinol., 136, p. 369
Van Royen, E. A., Verhoeff, N. P. L. G., Meylaerts, S. A. G., Miedema, A. R., Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands (1996) J. Nucl. Med., 37, p. 1449
Bakker, W. H., Albert, R., Bruns, C., Breeman, W. A. P., Hofland, L. J., Marbach, P., Pless, J., Krenning, E. P., [111In-DTPA-D-Phe1] -octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation (1991) Life Sci., 49, p. 1583
De Bruin, T. W. A., Kwekkeboom, D. J., V'Ant Verlaat, J. W., Reubi, J. -C., Krenning, E. P., Lamberts, S. W. J., Croughs, R. J. M., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro (1992) J. Clin. Endocrinol. Metab., 75, p. 1310
Reubi, J. -C., Landolt, A. M., High density o somatostatin receptors in pituitary tumors from acromegalic patients (1984) Clin. Endocrinol. Metab., 59, p. 1148
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas
The aim of this study was to compare the pituitary In-111-DTPA-D-Phe(1)-octreotide uptake measured in 49 patients subjected to the scintigraphy for SS-R expressing tumors not located in the sellar region with that measured in 38 patients with pituitary adenomas. The 87 subjects enrolled in this study were divided into two groups: the first included SSR-expressing tumors (SS-ET), 10 thymomas, 13 differentiated thyroid carcinomas, 4 carcinoids, 5 neuroendocrine tumors, 5 insulinomas, 6 melanomas, 2 renal carcinomas, 2 pheocromocytomas, and 2 parathyroid tumors, while the second included pituitary adenomas, 25 GH-secreting, 4 GH/PRL-mixed and 9 clinically nonfunctioning adenomas (NFA). Planar and single-photon-emission tomography images of the head were obtained 2-4 and 24 hours after the injection of 77-103 MBq of In-111-DTPA-D-Phe(1)-octreotide and pituitary uptake was measured by the region of interest method. A 4 point score was used to grade the pituitary-to-blood (T-to-B) ratios: 0=negative; 1=faint (T-to-B=3.5). In patients with pituitary adenomas, the percent suppression of GH and alpha-subunit levels after 6-12 months of octreotide treatment (0.3-0.6 mg/day) was correlated to T-to-B ratios. After 2-4 hr from injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in 2 out of 49 SS-ET (4%), 18 out of 29 acromegalics (62%) and 6 NFA (66.6%), while a faint uptake was detected in 4 SS-ET (8%), 8 GH-secreting adenomas (27.5%) and 3 NFA (33.3%). Negative scan was detected in the remaining 43 SS-ET (87.7%) and 3 GH-secreting microadenomas (10.3%). 24 hr after injection, pituitary In-111-DTPA-D-Phe(1)-octreotide uptake was moderate/intense in SS-ET (10.2%), 21 GH-secreting adenomas (72.4%), and 9 NFA (100%) while a faint uptake was detectable in 15 SS-ET (30.6%), and 6 GH-secreting adenomas (20.7%). No uptake was visualized in 29 SS-ET, and 2 GH-secreting adenomas. By MRI a pituitary tumor was shown in the 2 SS-ET with early moderate tracer uptake. Normalization of circulating GH/IGF-I levels and suppression of alpha-subunit levels was achieved in 16 of 18 acromegalics (88.9%) and 5 of 6 NEA-bearing patients, respectively, with scan scored 2-3 at early images. Eleven acromegalics (37.9%) and 2 NFA (22.2%) displayed significant tumor shrinkage (greater than or equal to 30% of baseline size) during long-term octreotide therapy. Both in GH-secreting and in NEA, a significant correlation was found between percent GH or alpha-subunit suppression after 6-12 months of octreotide therapy and T-to-B ratios both in early (r=0.626; p
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas